Literature DB >> 15797629

Frequent overexpression of cyclin D2/cyclin-dependent kinase 4 in Wilms' tumor.

Marine Faussillon1, Lucie Monnier, Claudine Junien, Cécile Jeanpierre.   

Abstract

The expression status of the three cyclin D genes (CCND1, CCND2 and CCND3), the two cyclin D-dependent kinase genes (CDK4 and CDK6) and the p16(INK4a) gene was studied in a series of 47 Wilms' tumors, 16 normal mature kidneys and two fetal kidneys. We showed predominant overexpression of CCND2 and CDK4 compared to CCND1/D3 and CDK6 respectively. We found a specific correlation between relapse and CDK4 overexpression, but not CDK6 overexpression. We did not identify any methylation of the p16(INK4a) promoter. This suggests that dysregulation of CCND2 and CDK4 plays a specific role in WT tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15797629     DOI: 10.1016/j.canlet.2004.08.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.

Authors:  Mary E Olanich; Wenyue Sun; Stephen M Hewitt; Zied Abdullaev; Svetlana D Pack; Frederic G Barr
Journal:  Clin Cancer Res       Date:  2015-03-25       Impact factor: 12.531

Review 2.  The stem cell identity of testicular cancer.

Authors:  Amander T Clark
Journal:  Stem Cell Rev       Date:  2007-01       Impact factor: 5.739

3.  Immunoreactivity of p27(Kip1), cyclin D3, and Ki67 in conventional renal cell carcinoma.

Authors:  Ambrosi Pertia; David Nikoleishvili; Omar Trsintsadze; Nino Gogokhia; Laurent Managadze; Archil Chkhotua
Journal:  Int Urol Nephrol       Date:  2008-08-05       Impact factor: 2.370

4.  Expression of p27((Kip1)), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells.

Authors:  David Nikoleishvili; Ambrosi Pertia; Omar Trsintsadze; Nino Gogokhia; Laurent Managadze; Archil Chkhotua
Journal:  Int Urol Nephrol       Date:  2008-03-04       Impact factor: 2.370

5.  A new description of cellular quiescence.

Authors:  Hilary A Coller; Liyun Sang; James M Roberts
Journal:  PLoS Biol       Date:  2006-03-07       Impact factor: 8.029

6.  MiR-1 downregulation correlates with poor survival in clear cell renal cell carcinoma where it interferes with cell cycle regulation and metastasis.

Authors:  Haibing Xiao; Jin Zeng; Heng Li; Ke Chen; Gan Yu; Junhui Hu; Kun Tang; Hui Zhou; Qihong Huang; Anping Li; Yi Li; Zhangqun Ye; Ji Wang; Hua Xu
Journal:  Oncotarget       Date:  2015-05-30

7.  Cell Cycle-independent Role of Cyclin D3 in Host Restriction of Influenza Virus Infection.

Authors:  Ying Fan; Chris Ka-Pun Mok; Michael Chi Wai Chan; Yang Zhang; Béatrice Nal; François Kien; Roberto Bruzzone; Sumana Sanyal
Journal:  J Biol Chem       Date:  2017-01-27       Impact factor: 5.157

8.  Combined Genetic and Chromosomal Characterization of Wilms Tumors Identifies Chromosome 12 Gain as a Potential New Marker Predicting a Favorable Outcome.

Authors:  Masayuki Haruta; Yasuhito Arai; Hajime Okita; Yukichi Tanaka; Tetsuya Takimoto; Ryuichi P Sugino; Yasuhiro Yamada; Takehiko Kamijo; Takaharu Oue; Masahiro Fukuzawa; Tsugumichi Koshinaga; Yasuhiko Kaneko
Journal:  Neoplasia       Date:  2018-12-06       Impact factor: 5.715

9.  High cyclin E staining index in blastemal, stromal or epithelial cells is correlated with tumor aggressiveness in patients with nephroblastoma.

Authors:  Dominique Berrebi; Julie Leclerc; Gudrun Schleiermacher; Isabelle Zaccaria; Liliane Boccon-Gibod; Monique Fabre; Francis Jaubert; Alaa El Ghoneimi; Cécile Jeanpierre; Michel Peuchmaur
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

10.  Genetic and epigenetic analyses guided by high resolution whole-genome SNP array reveals a possible role of CHEK2 in Wilms tumour susceptibility.

Authors:  Sara Ciceri; Beatrice Gamba; Paola Corbetta; Patrizia Mondini; Monica Terenziani; Serena Catania; Marilina Nantron; Maurizio Bianchi; Paolo D'Angelo; Federica Torri; Fabio Macciardi; Paola Collini; Martina Di Martino; Fraia Melchionda; Andrea Di Cataldo; Filippo Spreafico; Paolo Radice; Daniela Perotti
Journal:  Oncotarget       Date:  2018-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.